Earlier studies have found that MAP2 polyclonal antibody might label abnormal neurites around senile plaques [26], and accumulation of soluble Aβ oligomers in a transgenic mouse model of AD results in a decrease in MAP2 labeling before these mice develop plaques [12], suggesting a possible role of MAP2 in neurodegenerative diseases. This evidence concerns the gene MAP2 and Alzheimer disease.